Search
Sibrotuzumab
go.drugbank.com/drugs/DB06474InvestigationalSibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer.
Biomed 101
go.drugbank.com/drugs/DB05851InvestigationalBiomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma. Biomed 101 is a solid. … Biomed 101 binds to the leukotriene B4 receptor, but does not affect interleukin-2 antitumor activity.
Fontolizumab
go.drugbank.com/drugs/DB05111InvestigationalFontolizumab (marketed under the trade name HuZAF™) is a humanized monoclonal antibody which is used as an immunosuppressive drug to treat Crohn's disease.
Adenosine phosphate
go.drugbank.com/drugs/DB00131ApprovedInvestigationalNutraceuticalWithdrawnAdenosine phosphate, or adenylic acid, is an adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. … Adenosine phosphate was withdrawn by the FDA since it was considered neither safe nor effective for its intended uses as a vasodilator and an anti-inflammatory.[L43937]
Synonyms: Adenosine-5'P, 5'-O-PhosphonoadenosineInternational brands: My-B-DenBiricodar
go.drugbank.com/drugs/DB04851InvestigationalThe pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).
Categories: P-glycoprotein inhibitors, Heterocyclic Compounds, 1-RingCholic Acid
go.drugbank.com/drugs/DB02659ApprovedInvestigationalA major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. … [PubChem] Cholic acid, formulated as Cholbam capsules, is approved by the United States Food and Drug Administration as a treatment for children and adults with bile acid synthesis disorders due to single
Categories: P-glycoprotein inducersProducts: CHOLBAM® 50MG, ORPHACOL®50 MGAlbinterferon Alfa-2B
go.drugbank.com/drugs/DB05396InvestigationalIn response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug. … The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C.
Synonyms: alb-IFNCategories: Interferon Type I, Cytochrome P-450 CYP1A2 InhibitorsSulfapyridine
go.drugbank.com/drugs/DB00891ApprovedWithdrawnAntibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed.
Synonyms: N(1)-2-Pyridylsulfanilamide, N-2-PyridylsulfanilamideCategories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsEnzastaurin
go.drugbank.com/drugs/DB06486InvestigationalEnzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of
Categories: Heterocyclic Compounds, 2-Ring